广泛使用SGLT2i和GLP-1 RA时2型糖尿病主要心血管与肾脏并发症的发病率及费用预测:成本效果分析
研究基于澳大利亚糖尿病登记数据构建微观模拟模型,预测2020至2040年SGLT2i或GLP-1 RA广泛使用对2型糖尿病患者心梗、卒中、心衰和终末期肾病的健康经济影响。将SGLT2i或GLP-1 RA使用率提高至总人群75%或二级预防人群75%,与当前使用率比较。结果显示仅SGLT2i在考虑心血管和肾脏获益时具有成本效果,而GLP-1 RA不具有成本效果。
要点
- 将SGLT2i使用率提高至总人群75%可增加176,446个QALY,ICER为每QALY 23,717澳元。
- 将GLP-1 RA使用率提高至总人群75%可增加200,932个QALY,ICER为每QALY 100,705澳元。
- 在二级预防人群中,SGLT2i的ICER为每QALY 8,878澳元,GLP-1 RA为每QALY 79,742澳元。
核心结论
- 在当前价格下,仅考虑心血管和肾脏疾病获益时,使用SGLT2i具有成本效果,而使用GLP-1 RA不具有成本效果。
研究设计与样本
- modelled four interventions: increase in use of SGLT2is or GLP-1 RAs to 75% of the total population with type 2 diabetes, and increase in use of SGLT2is or GLP-1 RAs to 75% of the secondary prevention population (i.e. people with type 2 diabetes and prior CVD).
- 所有干预均与当前SGLT2i使用率(总人群20%)和GLP-1 RA使用率(总人群5%)进行比较。
- 结局指标包括质量调整生命年(QALY)、总成本(从澳大利亚公共医疗保健视角)和增量成本效果比(ICER),健康经济结局采用5%年贴现率,支付意愿阈值设定为每QALY 28,000澳元。
主要发现
- 在总人群(2020年n=1.1百万;2040年n=1.5百万)中,与当前使用相比,增加SGLT2i和GLP-1 RA使用从2020至2040年分别获得176,446和200,932个QALY。
- SGLT2i的净成本差异为42亿澳元,GLP-1 RA为202亿澳元,ICER分别为每QALY 23,717澳元和100,705澳元。
- 在二级预防人群中,SGLT2i的ICER为每QALY 8,878澳元,GLP-1 RA为每QALY 79,742澳元。
关键数值与推荐
- 支付意愿阈值设定为每QALY 28,000澳元。
- 健康经济结局采用5%年贴现率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Whether sodium-glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their cardiovascular and kidney benefits is unknown. We projected the health and economic outcomes due to myocardial infarction (MI), stroke, heart failure (HF) and end-stage kidney disease (ESKD) among people with type 2 diabetes, with and without CVD, under scenarios of widespread use of these drugs. METHODS: We designed a microsimulation model using real-world data that captured CVD and ESKD morbidity and mortality from 2020 to 2040. The populations and transition probabilities were derived by linking the Australian Diabetes Registry (1.1 million people with type 2 diabetes) to hospital admissions databases, the National Death Index and the ESKD Registry using data from 2010 to 2019. We modelled four interventions: increase in use of SGLT2is or GLP-1 RAs to 75% of the total population with type 2 diabetes, and increase in use of SGLT2is or GLP-1 RAs to 75% of the secondary prevention population (i.e. people with type 2 diabetes and prior CVD). All interventions were compared with current use of SGLT2is (20% of the total population) and GLP-1 RAs (5% of the total population). Outcomes of interest included quality-adjusted life years (QALYs), total costs (from the Australian public healthcare perspective) and the incremental cost-effectiveness ratio (ICER). We applied 5% annual discounting for health economic outcomes. The willingness-to-pay threshold was set at AU$28,000 per QALY gained. RESULTS: The numbers of QALYs gained from 2020 to 2040 with increased SGLT2i and GLP-1 RA use in the total population (n=1.1 million in 2020; n=1.5 million in 2040) were 176,446 and 200,932, respectively, compared with current use. Net cost differences were AU$4.2 billion for SGLT2is and AU$20.2 billion for GLP-1 RAs, and the ICERs were AU$23,717 and AU$100,705 per QALY gained, respectively. In the secondary prevention population, the ICERs were AU$8878 for SGLT2is and AU$79,742 for GLP-1 RAs. CONCLUSIONS/INTERPRETATION: At current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes.
引用
- Morton JI, Marquina C, Shaw JE, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2022. PMID: 36404375. doi:10.1007/s00125-022-05832-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。